Report: Outlook for cellular immunotherapy in immuno-oncology market positive in the long-term

12th May 2016 (Last Updated May 12th, 2016 18:30)

Cellular immunotherapy is poised to grow significantly in the future, rendering a positive effect on the immuno-oncology market, says a GlobalData report.

Cellular immunotherapy is poised to grow significantly in the future, rendering a positive effect on the immuno-oncology market, says a GlobalData report.

The growth in the immuno-oncology space is expected to be fuelled by immune checkpoint inhibitors in the near future, while cellular immunotherapy is predicted to have an impact only in the long-term.

Titled 'Immuno-Oncology Strategic Insight: Multi-Indication and Market Size Analysis', the report highlights the progress in cellular immunotherapy, which includes dendritic cell and chimeric antigen receptor T-cell (CAR-T) therapies.

It analyses that even though immune checkpoint inhibitors will spur the immuno-oncology market to a $34bn industry by 2024, cellular immunotherapies will continue to attract interest notwithstanding their past failures.

"Early studies of these drugs have demonstrated very impressive remission rates of up to 90%, although it is still too early to tell if these remissions will turn into cures."

CAR-T therapy has generated a lot of buzz since the start of the year, owing to promising results in a recently conducted preliminary clinical trial. The procedure is being studied as an effective and potential adoptive cell therapy for treating certain cancers.

Dan Roberts, Ph.D., GlobalData's senior analyst covering oncology and hematology, says: "Early studies of these drugs have demonstrated very impressive remission rates of up to 90%, although it is still too early to tell if these remissions will turn into cures.

"Downsides of CAR-T therapies include their association with severe immune toxicities, specifically cytokine release syndrome (CRS), which can be fatal."

The space for CAR-T therapy is currently led by Novartis' CAR-T therapy, CTL019, which is expected to receive an approval for treating acute leukaemia ahead of its competitors.

Other products that have received breakthrough therapy designation from the FDA include Juno Therapeutics' JCAR-015 and Kite Pharma's KTL-019.

Roberts continues: "Sales of cell therapies will be very low to 2024, especially when compared to checkpoint inhibitors.

"CAR-T cells, because of their high administration costs, are only primarily being developed in blood cancer populations, and GlobalData envisages that they will have overall low uptake and will be restricted to selected patients in large academic centres during the forecast period."